Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335774 · ClinicalTrials.gov registry record · Phase 2
Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids
A Phase 2 study of Internal Hemorrhoids, sponsored by Nivagen Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 2
- Study locations
NCT03335774 is a Phase 2 study of Internal Hemorrhoids that has completed, run by Nivagen Pharmaceuticals. The registered enrollment target is 103 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03335774, a Phase 2 study of Internal Hemorrhoids, has completed, sponsored by Nivagen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 2
- Study locations
Study Summary
A randomized, double-blind, placebo-controlled, multicenter, parallel group study of the safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic internal hemorrhoids.
Conditions Studied
Interventions
- DRUG Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
- DRUG Placebo (Vehicle) Suppository (Nivagen)
Study Locations (2)
North Carolina
- Clinical Research - Charlotte
Maharashtra
- Clinical Research - Navi Mumbai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2021-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03335774
The ClinicalTrials.gov registry entry for NCT03335774 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nivagen Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Internal Hemorrhoids appearing as the primary indexed condition, and to 2 interventions - of which Hydrocortisone Acetate Suppository, 25 mg (Nivagen) is the first listed.
NCT03335774 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Maharashtra.
Frequently Asked Questions
What is clinical trial NCT03335774 about?
NCT03335774 is a clinical study titled "Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids". A randomized, double-blind, placebo-controlled, multicenter, parallel group study of the safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic internal hemorrhoids.
What is the current status of trial NCT03335774?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2019-02-12. Estimated completion is 2021-03-05.
What conditions does trial NCT03335774 study?
This clinical trial studies the following conditions: Internal Hemorrhoids.
What interventions are being tested in trial NCT03335774?
The interventions under investigation include: Hydrocortisone Acetate Suppository, 25 mg (Nivagen) (DRUG), Placebo (Vehicle) Suppository (Nivagen) (DRUG).
Who is sponsoring clinical trial NCT03335774?
This trial is sponsored by Nivagen Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03335774 being conducted?
This trial has 2 study locations across North Carolina, Maharashtra. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Internal Hemorrhoids
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.